LakeShore Biopharma Co., Ltd (LSBCF) Stock
LSBCF is no longer traded. LakeShore Biopharma was delisted from the NYSE in June 2026.
Prices on this page are historical; the last trade was June 19, 2026 at $0.07.
LakeShore Biopharma stock price history
LSBCF final trading statistics
- Final close
- $0.07
- Final trading day
- Jun 19, 2026
- Market cap at delisting
- $2.88M
- Shares outstanding
- 41.21M
- Final 52-week range
- $0.03 – $1.48
- Avg. volume (final 3 mo.)
- 3,713
- All-time high (split-adj.)
- $101.40 · Mar 2023
- All-time low (split-adj.)
- $0.03 · Apr 2026
- Return since IPO
- -99.3%
- Beta
- 1.01
- Book value / share
- $3.55
- Price / book
- 0.02
LakeShore Biopharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $614.96M | -$100.0M | — |
| FY2024 | $573.42M | -$433.5M | -$30.57 |
| FY2023 | $687.20M | -$145.5M | — |
| FY2022 | $502.95M | -$236.7M | -$0.16 |
| FY2021 | $257.02M | -$191.8M | — |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
LakeShore Biopharma stock FAQ
What happened to LakeShore Biopharma stock?
LakeShore Biopharma stock was delisted from the NYSE. Its final close was $0.07 on June 19, 2026.
Is LSBCF stock still trading?
No. LSBCF was delisted from the NYSE in June 2026 and no longer trades on a U.S. exchange.
What was the last price of LSBCF stock?
LSBCF closed at $0.07 on its final trading day, June 19, 2026, for a market value of about $2.88M.
What were LakeShore Biopharma's revenue and earnings in its last full fiscal year?
LakeShore Biopharma reported revenue of $614.96M and net income of -$100.0M in fiscal 2025, its last full year as a public company.
When did LakeShore Biopharma go public?
LakeShore Biopharma Co., Ltd stock began trading on August 5, 2021.